The reported statements, read against the company's own industry.
Financials view
Market Capitalization
347.41MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Revenue (TTM)
31.98MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Profit Margin
-184.60%
vs Biotechnology peers
Updated Oct 28, 2026
Beta
0.5160x
vs all stocks
Updated Oct 28, 2026
52-Week Change
60.11%
vs all stocks
Updated Oct 28, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 28, 2026
Market Capitalization
347.41MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Enterprise Value
306.88MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Forward P/E
-3.68x
vs Biotechnology peers
Updated Oct 28, 2026
Price to Sales (TTM)
10.43x
vs Biotechnology peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 10.86×.Updated Oct 28, 2026
Price to Book (MRQ)
17.29x
vs Biotechnology peers
Updated Oct 28, 2026
Enterprise to Revenue
9.60x
vs Biotechnology peers
Updated Oct 28, 2026
Enterprise to EBITDA
-5.32x
vs Biotechnology peers
Updated Oct 28, 2026
Gross Margin
71.59%
vs Biotechnology peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 99.51%.Updated Oct 28, 2026
Profit Margin
-184.60%
vs Biotechnology peers
Updated Oct 28, 2026
Return on Assets (TTM)
-45.73%
vs Biotechnology peers
Updated Oct 28, 2026
Return on Equity (TTM)
-397.30%
vs Biotechnology peers
Updated Oct 28, 2026
Revenue (TTM)
31.98MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Revenue per Share (TTM)
0.5370USDUpdated Oct 28, 2026
Quarterly Revenue Growth
-89.50%
vs Biotechnology peers
Updated Oct 28, 2026
Gross Profit (TTM)
31.82MUSD
vs all stocks (USD)
Updated Oct 28, 2026
EBITDA (TTM)
-57.64MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Net Income (TTM)
-59.57MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Quarterly Earnings Growth (YoY)
-89.47%
vs Biotechnology peers
Updated Oct 28, 2026
Operating Cash Flow (TTM)
-58.32MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Levered Free Cash Flow (TTM)
-31.81MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 28, 2026
Trailing Annual Dividend Rate
0.00USDUpdated Oct 28, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 28, 2026
Revenue
33.48MUSDFY2025 · Dec 31, 2025
Cost of Goods Sold
190.00KUSDFY2025 · Dec 31, 2025
Gross Profit
33.29MUSDFY2025 · Dec 31, 2025
Operating Income
-51.81MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-52.70MUSDFY2025 · Dec 31, 2025
Net Income
-52.70MUSDFY2025 · Dec 31, 2025
EBIT
-51.55MUSDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-51.48MUSDFY2025 · Dec 31, 2025
Research & Development
58.19MUSDFY2025 · Dec 31, 2025
Selling, General & Administrative
26.91MUSDFY2025 · Dec 31, 2025
Non-operating Interest Expense
1.15MUSDFY2025 · Dec 31, 2025
EPS (Basic)
-1.11USDFY2025 · Dec 31, 2025
EPS (Diluted)
-1.11USDFY2025 · Dec 31, 2025
Basic Shares Outstanding
47.75MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
47.75MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-52.70MUSDFY2025 · Dec 31, 2025
Operating Cash Flow
-54.45MUSDFY2025 · Dec 31, 2025
Free Cash Flow
-54.94MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
34.69MUSDFY2025 · Dec 31, 2025
Interest Paid
1.45MUSDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-52.70MUSDFY2025 · Dec 31, 2025
Depreciation & Amortization
327.00KUSDFY2025 · Dec 31, 2025
Stock-based Compensation
11.98MUSDFY2025 · Dec 31, 2025
Other Non-cash Items
2.06MUSDFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-3.00KUSDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-16.11MUSDFY2025 · Dec 31, 2025
Capital Expenditures
-489.00KUSDFY2025 · Dec 31, 2025
Purchase of Investments
-76.31MUSDFY2025 · Dec 31, 2025
Sale of Investments
49.86MUSDFY2025 · Dec 31, 2025
Net Investing Cash Flow
-26.94MUSDFY2025 · Dec 31, 2025
Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025
Other Financing Charges
16.36MUSDFY2025 · Dec 31, 2025
Net Financing Cash Flow
88.24MUSDFY2025 · Dec 31, 2025
Shares Outstanding
60.11MSharesUpdated Oct 28, 2026
Float Shares
32.96MSharesUpdated Oct 28, 2026
Shares Short
2.55MSharesUpdated Oct 28, 2026
Short Ratio
7.00days
vs all stocks
Updated Oct 28, 2026
Short % of Shares Outstanding
6.88%
vs all stocks
Provider-reported. Shares Short ÷ Shares Outstanding on this page gives 4.24%.Updated Oct 28, 2026
% Held by Insiders
24.42%
vs all stocks
Updated Oct 28, 2026
% Held by Institutions
47.77%
vs all stocks
Updated Oct 28, 2026
Total Cash (MRQ)
109.96MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Total Cash per Share (MRQ)
1.83USDUpdated Oct 28, 2026
Total Debt (MRQ)
70.76MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Total Debt to Equity (MRQ)
2.41x
vs Biotechnology peers
Updated Oct 28, 2026
Current Ratio (MRQ)
8.26x
vs Biotechnology peers
Updated Oct 28, 2026
Book Value per Share (MRQ)
0.3210USDUpdated Oct 28, 2026
Total Assets
114.86MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
107.91MUSDFY2025 · Dec 31, 2025
Total Liabilities
61.29MUSDFY2025 · Dec 31, 2025
Total Non-current Assets
6.95MUSDFY2025 · Dec 31, 2025
Total Non-current Liabilities
44.55MUSDFY2025 · Dec 31, 2025
Total Current Liabilities
16.74MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
34.69MUSDFY2025 · Dec 31, 2025
Other Short-term Investments
71.82MUSDFY2025 · Dec 31, 2025
Accounts Receivable
95.00KUSDFY2025 · Dec 31, 2025
Inventory
310.00KUSDFY2025 · Dec 31, 2025
Accounts Payable
6.09MUSDFY2025 · Dec 31, 2025
Short-term Debt
751.00KUSDFY2025 · Dec 31, 2025
Deferred Revenue
0.00USDFY2025 · Dec 31, 2025
Long-term Debt
15.20MUSDFY2025 · Dec 31, 2025
Other Non-current Liabilities
16.79MUSDFY2025 · Dec 31, 2025
Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025
Retained Earnings
-362.58MUSDFY2025 · Dec 31, 2025
Total Shareholders' Equity
53.57MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
3.46USDUpdated Oct 28, 2026
52-Week High
6.50USDUpdated Oct 28, 2026
52-Week Change
60.11%
vs all stocks
Updated Oct 28, 2026
Beta
0.5160x
vs all stocks
Updated Oct 28, 2026
50-Day MA
5.63USDUpdated Oct 28, 2026
200-Day MA
4.50USDUpdated Oct 28, 2026
Avg 10-Day Volume
375.51KSharesUpdated Oct 28, 2026
Avg 30-Day Volume
343.46KSharesUpdated Oct 28, 2026
Diluted EPS (TTM)
-0.8600USDUpdated Oct 28, 2026
Other Income / Expense
254.00KUSDFY2025 · Dec 31, 2025
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -25404.5%, lower than 95% of its Biotechnology peers (median -30.3%)Significant